Accuracy in equianalgesic dosing: Conversion dilemmas

Journal of Pain and Symptom Management

Volumn 21, Issue 5, 2001, Pages 397-406

  Anderson, Robert ^a   Saiers, Joseph H ^a,b   Abram, Stephen ^a,b   Schlicht, Christian ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic pain; Equianalgesic dosing; Opioid rotation; Opioids; Palliative care

Indexed keywords

FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE SULFATE; OPIATE; OXYCODONE; OXYMORPHONE; SUFENTANIL;

ANALGESIA; CANCER PAIN; CHRONIC PAIN; DRUG DOSE; PALLIATIVE THERAPY; REVIEW;

ANALGESICS, OPIOID; HUMANS; NEOPLASMS; PAIN;

EID: 0035002085     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(01)00271-8     Document Type: Review

References (55)

1. Portnoy R.K. Cancer pain. epidemiology and syndromes Cancer. 63:1989;2298-2307.
2. Twycross R.G., Fairfield S. Pain in far advanced cancer. Pain. 14:1982;303-310.
3. Brescia F.J., Adler D., Gray G.et al. A profile of hospitalized advanced cancer patients. J Pain Symptom Manage. 5:1990;221-227.
4. Portenoy R.K., Miransky J., Thaleret al. Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics and impact. Cancer. 70:1992;1616-1624.
5. Cleeland C.S., Gonin R., Hatfield A.K.et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 330:1994;592-596.
6. Foley K.M. Pain relief into practice. rhetoric without reform J Clin Oncol. 13:1995;2149-2151.
7. Portnoy R.K., Kornblith A.B., Wong G.et al. Pain in ovarian cancer patients. prevalence, characteristics, and associated symptoms Cancer. 74:1994;907-915.
8. Bernabei R., Gambassi G., Lapane K.et al. Management of pain in elderly patients with cancer. JAMA. 279:1998;1877-1882.
9. Foley K.M. The treatment of cancer pain. N Engl J Med. 313:1985;84-95.
10. Inturrisi C.E. Management of cancer pain. Cancer. 63(Suppl):1989;2308-2320.
11. Zech D.F.J., Grond S., Lynch J.et al. Validation of World Health Organization guidelines for cancer pain relief. a 10-year prospective study Pain. 63:1995;65-76.
12. Levy M.H. Pharmacologic treatment of cancer pain. N Engl J Med. 335:1996;1124-1132.
13. Portnoy R.K., Moulin D.E., Robert A.et al. infusion of opioids for cancer pain. clinical review and guidelines for use Cancer Treat Rep. 70:1986;575-581.
14. Donahue S.R. Morphine sulfate intravenous dose of 1650 mg per hour. Hosp Pharm. 24:1989;311.
15. Ashby M.A., Martin P., Jackson K.A. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust. 170:1999;68-71.
16. Mercadante S. Opioid rotation for cancer pain. rationale and clinical aspects Cancer. 86:1999;1856-1866.
17. (Publication # 94-0593) Management of cancer pain. adults Am J Hosp Pharm. 51:1994;1643-1656.
18. Cherny N.I. Opioid analgesics. comparative features and prescribing guidelines Drugs. 51:1996;713-737.
19. Gordon D.B., Stevenson K.K., Griffie J.et al. Opioid equianalgesic calculations. J Palliat Med. 2:1999;209-218.
20. Beaver W.T., Wallenstein S.L., Rogers A.et al. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Clin Pharm Ther. 207:1978;101-108.
21. Beaver W.T., Wallenstein S.L., Rogers A.et al. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. J Clin Pharm Ther. 207:1978;92-100.
22. Kaplan R., Parris W.C.V., Citron M.L.et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol. 16:1998;3230-3237.
23. Kaiko R.F., Benzinger D.P., Fitzmartin R.D.et al. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmcol Ther. 59:1996;52-61.
24. Kalso E., Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 47:1990;639-646.
25. Inturrisi C.E., Foley K.M. Narcotic analgesics in the management of pain. Kuhar M., Pasternak G. Analgesics. neurochemical, behavioral and clinical perspectives:1984;257-288 Raven Press, New York.
26. Hagen N.A., Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer. 79:1997;1428-1437.
27. Zhukovsky D.S., Walsh D., Doona M. The relative potency between high dose oral oxycodone and intravenous morphine. a case illustration J Pain Symptom Manage. 18:1999;53-55.
28. Heiskanen T., Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain. 73:1997;37-45.
29. Bruera E., Belzile M., Pituskin E.et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol. 16:1998;3222-3229.
30. Bruera E., Pereira J., Watanabe S.et al. Opioid rotation in patients with cancer pain. Cancer. 78:1996;852-857.
31. Dunbar P.J., Chapman C.R., Buckley F.P.et al. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain. 68:1996;165-170.
32. Lawlor P., Turner K., Hanson J.et al. Dose ratio between morphine and hydromorphone in patients with cancer pain. a retrospective study Pain. 72:1997;79-85.
33. Coda B.A., O'Sullivan B., Donaldson G.et al. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplant. Pain. 72:1997;333-346.
34. Fainsinger R., Schoeller T., Bruera E. Methadone in the management of cancer pain. a review Pain. 52:1993;137-147.
35. Ripamonti C., Zecca E., Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 70:1997;109-115.
36. De Conno F., Groff L., Brunelli C.et al. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 14:1996;2836-2842.
37. Lawlor P.G., Turner K.S., Hanson J.et al. Dose ratio between morphine and methadone in patients with cancer pain. A retrospective study. Cancer. 82:1998;1167-1173.
38. Clark J.L., Kalen G.E. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid tolerant patient. J Pain Symptom Manage. 10:1995;310-314.
39. Hagen N.A., Wasylenko E. Methadone. Outpatient titration and monitoring strategies in cancer patients J Pain Symptom Manage. 18:1999;369-375.
40. Mercadante S., Casussio A., Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol. 17:1999;3307-3312.
41. Elliot K., Hynanski A., Inturrisi C.E. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain. 59:1994;361-368.
42. Gorman A., Elliott K., Inturrisi C.E. The d- and l-isomers of methadone bind to the noncompetitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 223:1997;5-8.
43. Shimoyama N., Shimoyama M., Megumi S.et al. d-methadone is antinociceptive in rat formalin test. J Pharmacol Exp Ther. 283:1997;648-652.
44. Codd E.E., Shank R.P., Schupsky J.J.et al. Serotonin and norepinephrine inhibiting activity of centrally acting analgesics. structural determinants and role in antinociception J Pharmacol Exp Ther. 274:1995;1263-1270.
45. Gagnon B., Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage. 18:1999;120-125.
46. Makin M.K., O'Donnell V., Skinner J.M.et al. Methadone in the management of cancer related neuropathic pain. Pain Clin. 10:1998;275-279.
47. Ripamonti C., Groff L., Brunelli C.et al. Switching from morphine to oral methadone in treating cancer pain. what is the equianalgesic dose ratio? J Clin Oncol. 16:1998;3216-3221.
48. Dosage Coversion Calculator (JPI-DR-298), Janssen Pharmaceuticals Inc., 1997.
49. Paix A., Coleman A., Lees J.et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain. 63:1995;263-269.
50. Donner B., Zenz M., Tryba M., Strumpf M. Direct conversion from oral morphine to transdermal fentanyl. a multicenter study in patients with cancer pain Pain. 64:1996;527-534.
51. Watanabe S., Pereira J., Hanson J., Bruera E. Fentanyl by continuous subcutaneous infusion for the management of cancer pain. a retrospective study J Pain Symptom Manage. 16:1998;323-326.
52. Hunt R., Fazekas B., Thorne D.et al. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage. 18:1999;111-119.
53. Lehmann K.A. Patient-controlled intravenous analgesia for postoperative pain relief. Max M.B., Portenoy R.K., Laska E.M. Advances in pain research and therapy. 1991;481-506 Raven Press, New York.
54. Kunz K.M., Theisen J.A., Schroeder M.E. Severe episodic pain. management with sublingual sufentanil J Pain Symptom Manage. 8(4):1993;189-190. [letter].
55. Duttaroy A., Yoburn B.C. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 82:1995;1226-1236.